Hemophilia B - Pipeline Insight and Competitive Landscape Report, 2026 | Gene Therapy and CRISPR Advances Unlock Growth Across 20+ Drugs and 15+ Companies
Dublin, Oct. 14, 2026 (GLOBE NEWSWIRE) -- "Hemophilia B - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The report delivers a comprehensive analysis of the Hemophilia B pipeline, covering 15+ companies and 20+ investigational drugs across clinical, preclinical and discovery stages. It evaluates pipeline candidates by development phase, product type, route of administration and molecule type, while also assessing discontinued and inactive products.
Hemophilia B is an inherited bleeding disorder associated with mutations in the F9 gene and a deficiency or dysfunction of coagulation factor IX. The condition is predominantly inherited in an X-linked recessive pattern, although spontaneous mutations can occur. Reduced or absent factor IX activity disrupts the intrinsic coagulation pathway, limits factor X activation and impairs fibrin formation, resulting in unstable clot formation and ineffective hemostasis.
Current Hemophilia B treatment primarily relies on recombinant or plasma-derived factor IX concentrates administered prophylactically or during bleeding episodes. Extended half-life factor IX products and gene therapies are expanding the treatment landscape by seeking to reduce infusion frequency, improve factor IX activity and provide sustained protection from bleeding.
Hemophilia B Pipeline Analysis
The report provides detailed commercial and clinical assessments of emerging Hemophilia B therapies. Individual drug profiles include mechanisms of action, clinical trial activity, regulatory designations, NDA approvals where applicable and product development updates. The analysis also reviews collaborations, licensing agreements, mergers and acquisitions, funding activities and technologies influencing Hemophilia B research and development.
Companies and academic organizations are investigating novel approaches designed to address unmet needs associated with treatment burden, bleeding control and long-term factor IX expression. The Hemophilia B pipeline includes late-stage, mid-stage and early-stage clinical candidates, as well as preclinical and discovery programs.
Selected Emerging Hemophilia B Drugs
Therapeutic Assessment and Development Stages
The report categorizes Hemophilia B pipeline products across Phase III, Phase II, Phase I, preclinical and discovery stages. It also examines discontinued and inactive candidates to provide a broader view of development trends, clinical progress and pipeline attrition.
Pipeline therapies are assessed across routes of administration that include intra-articular, intraocular, intrathecal, intravenous, ophthalmic, oral, parenteral, subcutaneous, topical and transdermal delivery. Molecule type analysis includes oligonucleotides, peptides and small molecules, while product classifications cover mono, combination and mono/combination therapies.
Key Hemophilia B Companies
Key Hemophilia B Pipeline Products
Report Scope and Strategic Insights
The report examines the number of companies developing Hemophilia B drugs, the distribution of candidates by company and phase, and the clinical status of emerging therapies. It also analyzes Industry-Industry and Industry-Academia collaborations, licensing activity, mergers and acquisitions, regulatory designations, novel drug types and technologies intended to overcome the limitations of existing treatments.
Additional insights include pipeline product profiles, therapeutic assessments, unmet needs, expected drug impact and development activity across the Hemophilia B market. This analysis supports pharmaceutical companies, biotechnology developers, investors and other industry stakeholders seeking to understand the competitive landscape and future direction of Hemophilia B treatment.
Key Topics Covered:
Introduction
Executive Summary
Hemophilia B: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hemophilia B- Analytical Perspective
Late Stage Products (Phase III)
ANB-002: Biocad
Mid Stage Products (Phase II)
Early Stage Products (Phase I/II)
REGV131-LNP1265: Regeneron Pharmaceuticals Inc./ Intellia Therapeutics, Inc.
Preclinical and Discovery Stage Products
Inactive Products
Hemophilia B Key Companies
Hemophilia B Key Products
Hemophilia B - Unmet Needs
Hemophilia B - Market Drivers and Barriers
Hemophilia B - Future Perspectives and Conclusion
Hemophilia B Analyst Views
Appendix
List of Tables [12]
List of Figures [12]
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/byon93
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.